Istanbul University

Background: in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives: to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations: sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions: EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.

The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles ("MISEV") guidelines for the field in 2014. We now update these "MISEV2014" guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV-associated functional activities. Finally, a checklist is provided with summaries of key points.

The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them. REM sleep behavior disorder, severe neuroleptic sensitivity, and reduced striatal dopamine transporter activity on functional neuroimaging are given greater diagnostic weighting as features suggestive of a DLB diagnosis. The 1-year rule distinguishing between DLB and Parkinson disease with dementia may be difficult to apply in clinical settings and in such cases the term most appropriate to each individual patient should be used. Generic terms such as Lewy body (LB) disease are often helpful. The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that these are associated with the clinical DLB syndrome. Finally, the authors suggest patient management guidelines including the need for accurate diagnosis, a target symptom approach, and use of appropriate outcome measures. There is limited evidence about specific interventions but available data suggest only a partial response of motor symptoms to levodopa: severe sensitivity to typical and atypical antipsychotics in approximately 50%, and improvements in attention, visual hallucinations, and sleep disorders with cholinesterase inhibitors.

OBJECTIVE: The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present work, by a joint committee of the ACR and the European League Against Rheumatism (EULAR), was undertaken for the purpose of developing new classification criteria for SSc. METHODS: Using consensus methods, 23 candidate items were arranged in a multicriteria additive point system with a threshold to classify cases as SSc. The classification system was reduced by clustering items and simplifying weights. The system was tested by 1) determining specificity and sensitivity in SSc cases and controls with scleroderma-like disorders, and 2) validating against the combined view of a group of experts on a set of cases with or without SSc. RESULTS: It was determined that skin thickening of the fingers extending proximal to the metacarpophalangeal joints is sufficient for the patient to be classified as having SSc; if that is not present, 7 additive items apply, with varying weights for each: skin thickening of the fingers, fingertip lesions, telangiectasia, abnormal nailfold capillaries, interstitial lung disease or pulmonary arterial hypertension, Raynaud's phenomenon, and SSc-related autoantibodies. Sensitivity and specificity in the validation sample were, respectively, 0.91 and 0.92 for the new classification criteria and 0.75 and 0.72 for the 1980 ACR classification criteria. All selected cases were classified in accordance with consensus-based expert opinion. All cases classified as SSc according to the 1980 ACR criteria were classified as SSc with the new criteria, and several additional cases were now considered to be SSc. CONCLUSION: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria for SSc and should allow for more patients to be classified correctly as having the disease.

Obesity is a chronic metabolic disease characterised by an increase of body fat stores. It is a gateway to ill health, and it has become one of the leading causes of disability and death, affecting not only adults but also children and adolescents worldwide. In clinical practice, the body fatness is estimated by BMI, and the accumulation of intra-abdominal fat (marker for higher metabolic and cardiovascular disease risk) can be assessed by waist circumference. Complex interactions between biological, behavioural, social and environmental factors are involved in regulation of energy balance and fat stores. A comprehensive history, physical examination and laboratory assessment relevant to the patient's obesity should be obtained. Appropriate goals of weight management emphasise realistic weight loss to achieve a reduction in health risks and should include promotion of weight loss, maintenance and prevention of weight regain. Management of co-morbidities and improving quality of life of obese patients are also included in treatment aims. Balanced hypocaloric diets result in clinically meaningful weight loss regardless of which macronutrients they emphasise. Aerobic training is the optimal mode of exercise for reducing fat mass while a programme including resistance training is needed for increasing lean mass in middle-aged and overweight/obese individuals. Cognitive behavioural therapy directly addresses behaviours that require change for successful weight loss and weight loss maintenance. Pharmacotherapy can help patients to maintain compliance and ameliorate obesity-related health risks. Surgery is the most effective treatment for morbid obesity in terms of long-term weight loss. A comprehensive obesity management can only be accomplished by a multidisciplinary obesity management team. We conclude that physicians have a responsibility to recognise obesity as a disease and help obese patients with appropriate prevention and treatment. Treatment should be based on good clinical care, and evidence-based interventions; should focus on realistic goals and lifelong multidisciplinary management.

Dementia has been increasingly more recognized to be a common feature in patients with Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of dementia associated with PD (PD-D), however, have been lacking. A Task Force, organized by the Movement Disorder Study, was charged with the development of clinical diagnostic criteria for PD-D. The Task Force members were assigned to sub-committees and performed a systematic review of the literature, based on pre-defined selection criteria, in order to identify the epidemiological, clinical, auxillary, and pathological features of PD-D. Clinical diagnostic criteria were then developed based on these findings and group consensus. The incidence of dementia in PD is increased up to six times, point-prevelance is close to 30%, older age and akinetic-rigid form are associated with higher risk. PD-D is characterized by impairment in attention, memory, executive and visuo-spatial functions, behavioral symptoms such as affective changes, hallucinations, and apathy are frequent. There are no specific ancillary investigations for the diagnosis; the main pathological correlate is Lewy body-type degeneration in cerebral cortex and limbic structures. Based on the characteristic features associated with this condition, clinical diagnostic criteria for probable and possible PD-D are proposed.

BACKGROUND: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. METHODS: In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ratio, to receive intravenous patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks. The primary end point was the change from baseline in the modified Neuropathy Impairment Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment) at 18 months. Other assessments included the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating worse quality of life), 10-m walk test (with gait speed measured in meters per second), and modified body-mass index (modified BMI, defined as [weight in kilograms divided by square of height in meters]×albumin level in grams per liter; lower values indicated worse nutritional status). RESULTS: A total of 225 patients underwent randomization (148 to the patisiran group and 77 to the placebo group). The mean (±SD) mNIS+7 at baseline was 80.9±41.5 in the patisiran group and 74.6±37.0 in the placebo group; the least-squares mean (±SE) change from baseline was -6.0±1.7 versus 28.0±2.6 (difference, -34.0 points; P<0.001) at 18 months. The mean (±SD) baseline Norfolk QOL-DN score was 59.6±28.2 in the patisiran group and 55.5±24.3 in the placebo group; the least-squares mean (±SE) change from baseline was -6.7±1.8 versus 14.4±2.7 (difference, -21.1 points; P<0.001) at 18 months. Patisiran also showed an effect on gait speed and modified BMI. At 18 months, the least-squares mean change from baseline in gait speed was 0.08±0.02 m per second with patisiran versus -0.24±0.04 m per second with placebo (difference, 0.31 m per second; P<0.001), and the least-squares mean change from baseline in the modified BMI was -3.7±9.6 versus -119.4±14.5 (difference, 115.7; P<0.001). Approximately 20% of the patients who received patisiran and 10% of those who received placebo had mild or moderate infusion-related reactions; the overall incidence and types of adverse events were similar in the two groups. CONCLUSIONS: In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number, NCT01960348 .).

Schizophrenia has a heritability of 60–80%1, much of which is attributable to common risk alleles. Here, in a two-stage genome-wide association study of up to 76,755 individuals with schizophrenia and 243,649 control individuals, we report common variant associations at 287 distinct genomic loci. Associations were concentrated in genes that are expressed in excitatory and inhibitory neurons of the central nervous system, but not in other tissues or cell types. Using fine-mapping and functional genomic data, we identify 120 genes (106 protein-coding) that are likely to underpin associations at some of these loci, including 16 genes with credible causal non-synonymous or untranslated region variation. We also implicate fundamental processes related to neuronal function, including synaptic organization, differentiation and transmission. Fine-mapped candidates were enriched for genes associated with rare disruptive coding variants in people with schizophrenia, including the glutamate receptor subunit GRIN2A and transcription factor SP4, and were also enriched for genes implicated by such variants in neurodevelopmental disorders. We identify biological processes relevant to schizophrenia pathophysiology; show convergence of common and rare variant associations in schizophrenia and neurodevelopmental disorders; and provide a resource of prioritized genes and variants to advance mechanistic studies. A genome-wide association study including over 76,000 individuals with schizophrenia and over 243,000 control individuals identifies common variant associations at 287 genomic loci, and further fine-mapping analyses highlight the importance of genes involved in synaptic processes.

The chemical diversity of antioxidants makes it difficult to separate and quantify antioxidants from the vegetable matrix. Therefore, it is desirable to establish a method that can measure the total antioxidant activity level directly from vegetable extracts. The current literature clearly states that there is no "total antioxidant" as a nutritional index available for food labeling because of the lack of standard quantitation methods. Thus, this work reports the development of a simple, widely applicable antioxidant capacity index for dietary polyphenols and vitamins C and E, utilizing the copper(II)-neocuproine [Cu(II)-Nc] reagent as the chromogenic oxidizing agent. Because the copper(II) (or cupric) ion reducing ability of polyphenols is measured, the method is named by our research group "cupric reducing antioxidant capacity" abbreviated as the CUPRAC method. This method should be advantageous over the ferric reducing antioxidant power (FRAP) method because the redox chemistry of copper(II)-as opposed to that of ferric ion-involves faster kinetics. The method comprises mixing of the antioxidant solution (directly or after acid hydrolysis) with a copper(II) chloride solution, a neocuproine alcoholic solution, and an ammonium acetate aqueous buffer at pH 7 and subsequent measurement of the developed absorbance at 450 nm after 30 min. Because the color development is fast for compounds such as ascorbic acid, gallic acid, and quercetin but slow for naringin and naringenin, the latter compounds were assayed after incubation at 50 degrees C on a water bath for 20 min [after Cu(II)-Nc reagent addition] so as to force the oxidation reaction to reach completion. The flavonoid glycosides were hydrolyzed to their corresponding aglycons by refluxing in 1.2 M HCl-containing 50% MeOH so as to exert maximal reducing power toward Cu(II)-Nc. Certain compounds also needed incubation after acid hydrolysis to fully exhibit their reducing capability. The CUPRAC antioxidant capacities of synthetic mixtures of antioxidants were experimentally measured as Trolox equivalents and compared to those theoretically found by making use of the principle of additivity of absorbances assuming no chemical interaction between the mixture constituents. Because ascorbic acid is not resistant to elevated temperature incubation, it should be assayed initially by measuring the absorbance (at 450 nm) difference of original and ascorbate oxidase-added mixture solutions at the end of 1 min of Cu(II)-Nc reagent addition. Thus, the total CUPRAC antioxidant capacity of a mixture containing various antioxidants should be that finally measured after a suitable combination of hydrolysis and incubation procedures, added to the initially measured capacity due to ascorbate. The antioxidant polyphenolic compounds tested demonstrate that the highest capacities in the CUPRAC method were observed for epicatechin gallate, epigallocatechin gallate, quercetin, fisetin, epigallocatechin, catechin, and caffeic acid in this order, in accordance with theoretical expectations, because the number and position of the hydroxyl groups as well as the degree of conjugation of the whole molecule are important. The antioxidant potency of flavonoids is nearly proportional to the total number of -OH groups and is positively affected by the presence of an o-dihydroxy moiety in the B-ring. beta-Carotene, which did not react with the CUPRAC reagent in alcoholic aqueous medium, could be assayed in dichloromethane solvent. Linear calibration curves for ascorbic acid and flavonoids were redrawn in synthetic solutions containing a mixture of antioxidants, and also in real matrices such as grape and orange juices, green tea, and blackberry tea, showing an initial nonzero absorbance with the CUPRAC reagent. The parallellism of the linear calibration curves of pure compounds in a given complex matrix effectively demonstrated that there were no interferent chemical interactions among the solution constituents and that the antioxidant capacities of the tested antioxidants were additive. The CUPRAC reagent is reasonably selective, stable, easily accessible, and sensitive toward thiol-type oxidants, unlike the FRAP method. The reaction is carried out at nearly physiological pH as opposed to the unrealistic acidic pH of FRAP.

Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and may be a harbinger of dementia. In view of its importance, the Movement Disorder Society commissioned a task force to delineate diagnostic criteria for mild cognitive impairment in PD. The proposed diagnostic criteria are based on a literature review and expert consensus. This article provides guidelines to characterize the clinical syndrome and methods for its diagnosis. The criteria will require validation, and possibly refinement, as additional research improves our understanding of the epidemiology, presentation, neurobiology, assessment, and long-term course of this clinical syndrome. These diagnostic criteria will support future research efforts to identify at the earliest stage those PD patients at increased risk of progressive cognitive decline and dementia who may benefit from clinical interventions at a predementia stage.

Humans express a wide array of ideal mate preferences. Around the world, people desire romantic partners who are intelligent, healthy, kind, physically attractive, wealthy, and more. In order for these ideal preferences to guide the choice of actual romantic partners, human mating psychology must possess a means to integrate information across these many preference dimensions into summaries of the overall mate value of their potential mates. Here we explore the computational design of this mate preference integration process using a large sample of n = 14,487 people from 45 countries around the world. We combine this large cross-cultural sample with agent-based models to compare eight hypothesized models of human mating markets. Across cultures, people higher in mate value appear to experience greater power of choice on the mating market in that they set higher ideal standards, better fulfill their preferences in choice, and pair with higher mate value partners. Furthermore, we find that this cross-culturally universal pattern of mate choice is most consistent with a Euclidean model of mate preference integration.

PURPOSE: Focal cortical dysplasias (FCD) are localized regions of malformed cerebral cortex and are very frequently associated with epilepsy in both children and adults. A broad spectrum of histopathology has been included in the diagnosis of FCD. An ILAE task force proposes an international consensus classification system to better characterize specific clinicopathological FCD entities. METHODS: Thirty-two Task Force members have reevaluated available data on electroclinical presentation, imaging, neuropathological examination of surgical specimens as well as postsurgical outcome. KEY FINDINGS: The ILAE Task Force proposes a three-tiered classification system. FCD Type I refers to isolated lesions, which present either as radial (FCD Type Ia) or tangential (FCD Type Ib) dyslamination of the neocortex, microscopically identified in one or multiple lobes. FCD Type II is an isolated lesion characterized by cortical dyslamination and dysmorphic neurons without (Type IIa) or with balloon cells (Type IIb). Hence, the major change since a prior classification represents the introduction of FCD Type III, which occurs in combination with hippocampal sclerosis (FCD Type IIIa), or with epilepsy-associated tumors (FCD Type IIIb). FCD Type IIIc is found adjacent to vascular malformations, whereas FCD Type IIId can be diagnosed in association with epileptogenic lesions acquired in early life (i.e., traumatic injury, ischemic injury or encephalitis). SIGNIFICANCE: This three-tiered classification system will be an important basis to evaluate imaging, electroclinical features, and postsurgical seizure control as well as to explore underlying molecular pathomechanisms in FCD.

Abbreviations ACE: angiotensin-converting enzyme; BP: blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; ESC: European Society of Cardiology; ESH: European Society of Hypertension; ET: endothelin; IMT: carotid intima-media thickness; JNC: Joint National Committee; LVH: left ventricular hypertrophy; LVM: left ventricular mass; PDE-5: phosphodiesterase-5; PPAR-γ: peroxisome proliferators-activated receptor-γ; PWV: pulse wave velocity; SBP: systolic blood pressure; WHO: World Health Organization. Introduction In the 2 years since the publication of the 2007 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) [1], research on hypertension has actively been pursued and the results of new important studies (including several large randomized trials of antihypertensive therapy) have been published. Some of these studies have reinforced the evidence on which the recommendations of the 2007 ESH/ESC guidelines were based. However, other studies have widened the information available in 2007, modifying some of the previous concepts, and suggesting that new evidence-based recommendations could be appropriate. The aim of this document of the ESH is to address a number of studies on hypertension published in the last 2 years in order to assess their contribution to our expanding knowledge of hypertension. Furthermore, some critical appraisal of the current recommendations of the ESH/ESC, as well as of other guidelines, might be a useful step toward the preparation of a third version of the European guidelines in the future. The most important conclusions are summarized in boxes. The points that will be discussed are reported in Box 1.Box. 1Assessment of subclinical organ damage for stratification of total cardiovascular risk The 2007 ESH/ESC guidelines recommend total cardiovascular risk be evaluated in each patient to decide about important aspects of treatment: the blood pressure (BP) threshold at which to commence drug administration, the target BP to be reached by treatment, the use of two-drug combinations as the initial treatment step, and the possible addition to the antihypertensive treatment regimen of lipid-lowering and antiplatelet agents [1]. Among the criteria to assess total cardiovascular risk, the European guidelines consider subclinical organ damage to be a very important component, because asymptomatic alterations of the cardiovascular system and the kidney are crucial intermediate stages in the disease continuum that links risk factors such as hypertension to cardiovascular events and death. On the basis of a number of criteria (prognostic importance, prevalence in the population, availability and cost of the assessment procedures, etc.), the 2007 European guidelines considered detection of organ damage as important for the diagnostic and prognostic evaluation of hypertensive patients. They further subdivided the different types of organ damage into (1) those that can be identified by relatively simple and cheap procedures [electrocardiogram, serum creatinine, estimated glomerular filtration rate (eGFR), and measurement of urinary protein excretion in order to detect microalbuminuria or proteinuria], which were thus regarded as suitable for routine search in the whole hypertensive population, and (2) those that require more complex procedures or instrumentations (echocardiogram, carotid ultrasonography, pulse wave velocity), which were for this reason only recommended for a more in-depth characterization of the hypertensive patient. Since then, other studies have added useful information on the importance of detecting subclinical organ damage in the hypertensive population, strengthening the recommendation to use the most easily available and the least costly procedures in the routine examination of individuals with hypertension. Heart A few recent papers have revived interest in the of the to the risk of cardiovascular In a a new of left ventricular the of left ventricular that is on and has been reported to be to cardiovascular The for and Furthermore, in the the have reported that in hypertensive with left individuals at risk of cardiovascular cardiovascular and for a very recent on the in as with left ventricular and of cardiovascular events hypertension is by risk for each evidence is available on the of as by of interest because of to more and and A has information more and hypertensive with left ventricular left ventricular left ventricular in of the left ventricular and and the risk of as large as that of with left ventricular in on population, the left ventricular and for and only in the risk with has been by other In a on a of hypertensive for with a of and cardiovascular events and with for cardiovascular risk factors Furthermore, a of hypertensive in the that cardiovascular events about more in with a or more with those with a this in the population, with a to in cardiovascular and were for a large number of and BP A in the risk more risk the The of carotid and with cardiovascular discussed in the 2007 guidelines, has been further by which have that carotid cardiovascular events of BP and and this for the at the carotid and for the at the of the carotid that by the at the and by the carotid prognostic in addition to that of prognostic of carotid has been reported in a of of the of cardiovascular which for about years has on the prognostic of arterial In the population, pulse wave with a in the risk of a cardiovascular Furthermore, of for cardiovascular events has been in for years of and wave such as BP and have been as of cardiovascular events in recent studies In in of these studies of and hypertensive only and cardiovascular for cardiovascular risk and carotid However, be that in most available the of BP pressure which the BP be considered in the of hypertensive in of further new the evidence on the prognostic of that available at the of the 2007 guidelines [1]. In the of in the with a of cardiovascular events and in the and with a in the of and cardiovascular events for cardiovascular risk and of in a of the to the of and to the different and more of the to the which only of The by the to be of and cardiovascular events in the large number of 2 in the were for the urinary protein excretion of the risk of cardiovascular events the in the risk of cardiovascular and events and evidence is available to the large of in of the prognostic of the in urinary protein as microalbuminuria In the and the microalbuminuria as important of cardiovascular the and in with microalbuminuria with those In the the of microalbuminuria with a In the a of to the with a and in the risk of cardiovascular cardiovascular and this the the to microalbuminuria The of urinary protein excretion and were of each other and the of microalbuminuria and about in for cardiovascular for cardiovascular and for of organ damage The 2007 European guidelines a number of of organ damage for which evidence of prognostic use in the could be because of of such as the cost and availability of the the and in the procedures, and in several the of of the and on the evidence available in the last 2 addition to the of organ damage in the 2007 guidelines can be the availability of more and the cost of their use about by In this the use of in a very recent in a of hypertensive cardiovascular disease has the information that are more and subclinical and in the of other of organ damage evidence these to a of importance because of the of the more and more in diagnostic procedures, disease is to more in prognostic and studies in hypertension. The prognostic of alterations in has been by studies However, the of this measurement of this A new for the of for evaluation to be on a of a that has been actively in the In a of individuals cardiovascular disease with hypertension and with the of the of cardiovascular this of cardiovascular risk factors in the large of of the Health added very to the prognostic of risk factors On the have reported that in a of hypertensive for about of the the with a in cardiovascular events for cardiovascular risk However, the of have reported that in the of hypertensive of cardiovascular events because in different have a different prognostic the prognostic of in hypertension to be further be that the addition of new of organ damage to the assessment of total cardiovascular risk only the of their prognostic importance, has to the to the of cardiovascular is by to be and are available that in some new risk factors of prognostic added to the the by which cardiovascular risk can be thus only the diagnostic procedures more and is by the recent results of the which that of to in the and by which total cardiovascular risk organ damage as a of cardiovascular risk subclinical organ damage the of cardiovascular risk, the the patient into the that risk of at least cardiovascular events in years patients. The 2007 European guidelines hypertensive with subclinical organ damage those with a total cardiovascular is further by more recent evidence on the contribution of subclinical and damage to the total cardiovascular to subclinical of the by some of the studies that in hypertensive of the is with of cardiovascular events to or in years in years has been reported for for with in the in the hypertensive of the with a of cardiovascular events of with the in evidence for In the of the Health the of cardiovascular events the carotid or more and and in those with in the In the hypertensive of the the of and cardiovascular events in years carotid in the third and or at least been In with in the or the cardiovascular events in In hypertensive the of cardiovascular events or more and in those with in the and Furthermore, asymptomatic disease as by a has been to be in with of cardiovascular events in years and recent evidence that in hypertensive subclinical organ damage is with a risk of cardiovascular events of or has been reported some years that by a serum more is with a of cardiovascular events or more In the recent of hypertensive a with cardiovascular events of about in with Furthermore, in the hypertensive by the of disease in years in the of microalbuminuria and of only in in the the of cardiovascular events in only in those individuals in microalbuminuria in the with in the of these hypertension. The 2007 European guidelines with subclinical organ damage as at risk BP is in the evidence that this is the is In the of the information available on the prognostic of in the and hypertensive Furthermore, in the population, the of with cardiovascular events for cardiovascular risk BP In the microalbuminuria with only a cardiovascular in that a risk to the and in the individuals of the a microalbuminuria the with a rate of cardiovascular events of only in years with a rate in individuals with microalbuminuria the of of subclinical organ damage The 2007 European guidelines have that of organ damage the of cardiovascular that organ damage be to the in the in which hypertensive in treatment by of or a in cardiovascular those in or to that in and in other studies a in and or cardiovascular with in treatment or in with a of cardiovascular events and to Since 2007, on the in damage and cardiovascular have been by further of the which have that in left left ventricular and in of with cardiovascular rate Furthermore, have been that in in treatment cardiovascular the of in the carotid has for the been in a recent of to a of the of these with the large in to conclusions The of in with cardiovascular has been by some of the In this on a large number of or very cardiovascular risk the with a of angiotensin-converting and the in the on with or the other this by a in cardiovascular events and with in events However, these results the important that in can be a of the more or of treatment because for the results are in most a and few which in a very number of the that for that Furthermore, in the very cardiovascular risk the of the system by the and might have of that and the with a in In of this are some recent of the in with 2 In these of a with and cardiovascular the contribution of to the of on the important prognostic of subclinical organ damage to In hypertensive and the population, the of and a carotid or arterial a by the or microalbuminuria or the total cardiovascular risk, hypertensive into the risk The in or by treatment the on cardiovascular information on are more or by the treatment some recent results evidence that this is the for in urinary protein the for the of subclinical organ damage is of crucial importance in the hypertensive assessment can use of simple and cheap procedures that can routine information and at can on more that can further and In organ damage assessment is useful because of the evidence that in the of of organ damage to the cardiovascular risk be more with to the cardiovascular risk is published subclinical organ damage can total cardiovascular risk to the in with However, organ damage is or or is by risk is with a or in risk in individuals and the 2007 guidelines recommend risk as a for the of treatment in and patients. In this is important to that the of organ damage in that decide to the of several studies that the of cardiovascular events is in in hypertensive for cardiovascular risk factors and is with the that antihypertensive treatment a total risk to a the that in treatment is organ damage is use of organ damage assessment thus to a more about the of treatment and thus Some of the discussed in of subclinical organ damage for stratification of total cardiovascular risk are summarized in Box guidelines on the management of hypertension recommend the of antihypertensive in with a or more a or and to the treatment in order for the to be these They further recommend drug treatment to be a BP that a and and a and in with or a of cardiovascular or at The 2007 ESH/ESC guidelines have these recommendations with information on the evidence are and a critical of this has been by of the in the of further information by recent The of the ESH document is to the and the of evidence on which these recommendations are and thus the and of studies which possible evidence to antihypertensive treatment recommend use of antihypertensive in with hypertension at or cardiovascular risk, that BP is and and treatment has However, be that the evidence in of this recommendation is because trials of on BP could be those hypertension or the recent which in the 2007 guidelines to in with cardiovascular risk, evidence because BP a large of antihypertensive at and a number of evidence of organ damage or a of cardiovascular to the or that the BP threshold for drug treatment is to and recommend antihypertensive at at least or at least in the as However, as in is on hypertensive that with a in the hypertension can be that current guidelines recommendations on BP at which to drug treatment in the are on results other and by the large of antihypertensive in available trials in the at initial blood and at in antihypertensive treatment trials in the is for the guidelines recommendation to drug treatment in the BP have are on the results of the of the which has important as a the the the in and a of cardiovascular events in the randomized to more treatment to the of to other cardiovascular of large and However, in by BP were and the of cardiovascular in the in the of antihypertensive treatment in with or in those in this were stratification on the or of a of hypertension. have been recommendations to antihypertensive treatment at BP in with previous have been on the the that in with a previous or BP by a in the of and cardiovascular events in hypertensive and patients. However, in this hypertension by of or and in a a in with treatment only or more Furthermore, BP in were reported of treatment in of the and be to on of treatment in patients. the of evidence of has been by the results of a more recent large of antihypertensive treatment in with the these results be to a more in a more discussed in the 2007 European guidelines and further in a recent trials are available the information drug treatment be at BP in with disease is in most to the of the to the which were in these were subdivided for their or BP on a of antihypertensive drug administration, and thus the to a BP the results and trials pressure The evidence available on the BP of antihypertensive treatment has been by some of this and is summarized in in the in of trials in hypertensive to in the actively at or this in the or In of the BP with a in and in this for that were and the in a previous were at or cardiovascular risk and with this evidence the recommendation of guidelines to to in the of with or 2 hypertension and or total cardiovascular this recommendation to hypertensive is by in the of in trials the of hypertensive randomized to more treatment a of cardiovascular in the only with results the were to is evidence in of the guidelines recommendation to the target in patients. The of that the guidelines recommendation to BP in with or a of cardiovascular disease is by the recommendation in of treatment to the by some such as and a of cardiovascular for a BP in in hypertensive patients. in the of only in were and were with a in cardiovascular results trials in with a of or disease with the that in some trials in which to with the with of of trials and trials on organ damage on BP and for drug treatment has been of trials and studies on the of treatment on organ damage of prognostic importance, this is of the of cardiovascular events in to the BP by treatment have been in the large of hypertensive of the in the cardiovascular risk for the the and the and in the with of the In the the of cardiovascular events at a of and a of In the hypertensive in the BP a in the of cardiovascular events and with to the in BP these of the of treatment In the the of cardiovascular events as the of in which BP to be were for and The cardiovascular with a for cardiovascular events to as the to about On the in the of BP were initial were for were and at each initial a BP by a cardiovascular However, in in initial in the the and for have been reported for the of in in the with of the of to to cardiovascular and to of as well as in disease to the BP and subclinical organ the have that the of is to the BP by treatment, the for large BP the A published has that of is by as with BP and in hypertensive Furthermore, several studies have evidence that antihypertensive treatment is by a or a in urinary protein be in the or initial BP is The most recent evidence has been by the which has that in most of antihypertensive treatment, further BP by the addition of and the of of the the or the of urinary protein a of initial systolic or diastolic BP to The for a and in the actively as with the at initial or and Furthermore, this of the has the risk of a to as the treatment to of about The has been some a for of on the of some trials as well as of the results of other trials on have the that in at cardiovascular risk, antihypertensive treatment that to or and be by a further in the of that by a has to the as to BP is and in of cardiovascular The is to the a BP which organ is studies in of cardiovascular disease that the BP and cardiovascular rate is to very BP which are only by antihypertensive is possible that in cardiovascular risk of the that blood the BP threshold which organ is However, the of this be different in to the of organ damage and has been by trials to the of more BP for initial and of results the that in the in which BP could have been a initial cardiovascular risk that the BP and the of cardiovascular this is by the evidence of a in of several trials these the of cardiovascular by a of BP that is and and suggesting that this BP the in cardiovascular are is in with the results of studies that the BP and cardiovascular events is cardiovascular events are on a which at BP the 2007 recommendations the evidence is to in hypertensive at and risk, drug be BP to or a suitable with with the to BP this of antihypertensive treatment in hypertension for BP to to 2 or organ damage to is by a recent of trials with antihypertensive agents has that in trials on cardiovascular risk the that the risk by lipid-lowering and antiplatelet can very the a cardiovascular events in by a initial risk On the in trials hypertensive at initial or risk, the could be to in which that of antihypertensive be threshold and target for drug treatment in the the current availability of well BP to be with in or in cardiovascular or of antihypertensive drug in with BP is by is the for the BP recommended for in large and are more in the subclinical organ and microalbuminuria and to be the to decide the BP for treatment as well as treatment in patients. and at least the of studies such as which the of BP or are be useful to recommend that in be well that are be in with the results of the in which the and of antihypertensive treatment were in in to with on in at recommendations can be to with previous cardiovascular for current evidence is of antihypertensive drug treatment BP is in the and the of at a BP target of has been in those with a BP that the 2007 ESH/ESC guidelines as at cardiovascular risk because of the of risk or subclinical organ has been that this BP subclinical organ damage to a cardiovascular risk, and is this The evidence in of in these is to that reported by the and the studies in which of antihypertensive drug the of hypertension the of the this be pursued with or with addition of antihypertensive agents last recommendations for a number of of patient management randomized trials can only for a few years and of the results to the of is The to into that the of antihypertensive treatment more with because of organ damage has a in with the of large and with a BP to be by the results of the few trials in which were for a number of years of randomized In the and for the of antihypertensive treatment on the of cardiovascular events years of the of the the that antihypertensive treatment in the A which is to as the has been reported for the 2 which reported a on the and of 2 years of with that antihypertensive and in the a of the of a previous blood in The most important points to threshold and target BP for treatment are summarized in and of antihypertensive In their and 2007 [1], the European guidelines the large number of randomized trials of antihypertensive those treatment and those treatment on different They that the of antihypertensive treatment are to of BP and are of the well as and and can BP and and cardiovascular these are suitable for the and of antihypertensive treatment as or in some combinations with each of the of the of antihypertensive and of agents a has been a in the by the of a by in and in the with the as for and the of by their has been by different of on a possible of and as well as on the possible of for and of for disease to possible or of new and is of and and be by of guidelines On the be to of the of The evidence which have been as antihypertensive and in the recommendations discussed in the 2007 European on the of in antihypertensive have been added since In a of of randomized trials of a has been reported the rate by and cardiovascular the the the the of and to be by On the a recent of randomized trials only a of in with other a as other agents on events and and a other in with a recent Furthermore, the recent publication of a of the and in has the of cardiovascular to be in on the or the with a in the is with of large of on different antihypertensive treatment for in randomized that the of cardiovascular on treatment on other antihypertensive agents has been of the possible of a BP by treatment in those trials in which to have a on of on in the of the that the very to the because of the in and On the to be to other antihypertensive agents in their to A recent more hypertensive different has a of in However, studies for the be with with other antihypertensive agents because of a wave to to be on antihypertensive management be because the and is to at hypertension and antihypertensive treatment are most is that as well as have and in such as those with the or The importance of this have been by the results of most studies and trials have been that by of in or in to of or with a blood a recent of the has that new of at the of this in at are by a number of in which of at at the of the However, the for Furthermore, is the as with some studies that with have a of cardiovascular the and several years the conclusions in other studies is with other agents in trials subclinical organ damage as have been to be and in left ventricular carotid and and this be to in cardiovascular in the be that are a and that such as and to some of the for other and pulse pressure at the BP rate and because of the with has on BP In the on total and and at has been to and to have the as and have been in trials in in and of the of and in treatment by and in the the on or with in of microalbuminuria and to in hypertensive and has been to and left ventricular pressure in the hypertensive the cardiovascular by and in with is in hypertension to be in a A for in antihypertensive such as that to these in the is of The evidence that a BP by can types of cardiovascular events is be that most of the the of which has been the basis for on have to the of these drug the of and is to and has been have been in for their to organ and have been to or Furthermore, large studies that have the of of antihypertensive agents on to have to with the least or those by the least on treatment a recent has reported for for In the results of the be discussed in the drug combinations have as to are the of and The that be to other antihypertensive agents in has been on the basis of some and A to the that be to in has been On the has been that be to in these concepts, as well as their have been by the results of the very large cardiovascular treatment with or has to be to as as the of a are A of on and more recent trials the that and have the on The by the relatively BP by treatment is more to because in and for could a is to decide the has to be with the of the several years or with the of the on to The of with a of cardiovascular events in because prevalence of in to that in or because of a of and have some information on the of and on the of new in patients. the that has been to of new different and in and only and were in and in with to the However, most were other antihypertensive agents that have the of the these the that a have been the of a of events by the the On the some recent that these agents have some in is this can be to a or to a BP in the patients. is are in as is in several studies and large The recent by that trials in which a BP antihypertensive and the

Protein coding genes constitute only approximately 1% of the human genome but harbor 85% of the mutations with large effects on disease-related traits. Therefore, efficient strategies for selectively sequencing complete coding regions (i.e., "whole exome") have the potential to contribute to the understanding of rare and common human diseases. Here we report a method for whole-exome sequencing coupling Roche/NimbleGen whole exome arrays to the Illumina DNA sequencing platform. We demonstrate the ability to capture approximately 95% of the targeted coding sequences with high sensitivity and specificity for detection of homozygous and heterozygous variants. We illustrate the utility of this approach by making an unanticipated genetic diagnosis of congenital chloride diarrhea in a patient referred with a suspected diagnosis of Bartter syndrome, a renal salt-wasting disease. The molecular diagnosis was based on the finding of a homozygous missense D652N mutation at a position in SLC26A3 (the known congenital chloride diarrhea locus) that is virtually completely conserved in orthologues and paralogues from invertebrates to humans, and clinical follow-up confirmed the diagnosis. To our knowledge, whole-exome (or genome) sequencing has not previously been used to make a genetic diagnosis. Five additional patients suspected to have Bartter syndrome but who did not have mutations in known genes for this disease had homozygous deleterious mutations in SLC26A3. These results demonstrate the clinical utility of whole-exome sequencing and have implications for disease gene discovery and clinical diagnosis.

CONTEXT: Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials. OBJECTIVE: To compare mortality and morbidity outcomes in patients with hypertension and CAD treated with a calcium antagonist strategy (CAS) or a non-calcium antagonist strategy (NCAS). DESIGN, SETTING, AND PARTICIPANTS: Randomized, open label, blinded end point study of 22 576 hypertensive CAD patients aged 50 years or older, which was conducted September 1997 to February 2003 at 862 sites in 14 countries. INTERVENTIONS: Patients were randomly assigned to either CAS (verapamil sustained release) or NCAS (atenolol). Strategies specified dose and additional drug regimens. Trandolapril and/or hydrochlorothiazide was administered to achieve blood pressure goals according to guidelines from the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) of less than 140 mm Hg (systolic) and less than 90 mm Hg (diastolic); and less than 130 mm Hg (systolic) and less than 85 mm Hg (diastolic) if diabetes or renal impairment was present. Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment. MAIN OUTCOME MEASURES: Primary: first occurrence of death (all cause), nonfatal myocardial infarction, or nonfatal stroke; other: cardiovascular death, angina, adverse experiences, hospitalizations, and blood pressure control at 24 months. RESULTS: At 24 months, in the CAS group, 6391 patients (81.5%) were taking verapamil sustained release; 4934 (62.9%) were taking trandolapril; and 3430 (43.7%) were taking hydrochlorothiazide. In the NCAS group, 6083 patients (77.5%) were taking atenolol; 4733 (60.3%) were taking hydrochlorothiazide; and 4113 (52.4%) were taking trandolapril. After a follow-up of 61 835 patient-years (mean, 2.7 years per patient), 2269 patients had a primary outcome event with no statistically significant difference between treatment strategies (9.93% in CAS and 10.17% in NCAS; relative risk [RR], 0.98; 95% confidence interval [CI], 0.90-1.06). Two-year blood pressure control was similar between groups. The JNC VI blood pressure goals were achieved by 65.0% (systolic) and 88.5% (diastolic) of CAS and 64.0% (systolic) and 88.1% (diastolic) of NCAS patients. A total of 71.7% of CAS and 70.7% of NCAS patients achieved a systolic blood pressure of less than 140 mm Hg and diastolic blood pressure of less than 90 mm Hg. CONCLUSION: The verapamil-trandolapril-based strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD patients.

MyD88 is a key downstream adapter for most Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs). MyD88 deficiency in mice leads to susceptibility to a broad range of pathogens in experimental settings of infection. We describe a distinct situation in a natural setting of human infection. Nine children with autosomal recessive MyD88 deficiency suffered from life-threatening, often recurrent pyogenic bacterial infections, including invasive pneumococcal disease. However, these patients were otherwise healthy, with normal resistance to other microbes. Their clinical status improved with age, but not due to any cellular leakiness in MyD88 deficiency. The MyD88-dependent TLRs and IL-1Rs are therefore essential for protective immunity to a small number of pyogenic bacteria, but redundant for host defense to most natural infections.

It would be desirable to establish and standardize methods that can measure the total antioxidant capacity level directly from vegetable extracts containing phenolics. Antioxidant capacity assays may be broadly classified as electron transfer (ET)- and hydrogen atom transfer (HAT)-based assays. The majority of HAT assays are kinetics-based, and involve a competitive reaction scheme in which antioxidant and substrate compete for peroxyl radicals thermally generated through the decomposition of azo compounds. ET-based assays measure the capacity of an antioxidant in the reduction of an oxidant, which changes colour when reduced. ET assays include the ABTS/TEAC, CUPRAC, DPPH, Folin-Ciocalteu and FRAP methods, each using different chromogenic redox reagents with different standard potentials. This review intends to offer a critical evaluation of existing antioxidant assays applied to phenolics, and reports the development by our research group of a simple and low-cost antioxidant capacity assay for dietary polyphenols, vitamins C and E, and human serum antioxidants, utilizing the copper(II)-neocuproine reagent as the chromogenic oxidizing agent, which we haved named the CUPRAC (cupric ion reducing antioxidant capacity) method. This method offers distinct advantages over other ET-based assays, namely the selection of working pH at physiological pH (as opposed to the Folin and FRAP methods, which work at alkaline and acidic pHs, respectively), applicability to both hydrophilic and lipophilic antioxidants (unlike Folin and DPPH), completion of the redox reactions for most common flavonoids (unlike FRAP), selective oxidation of antioxidant compounds without affecting sugars and citric acid commonly contained in foodstuffs and the capability to assay -SH bearing antioxidants (unlike FRAP). Other similar ET-based antioxidant assays that we have developed or modified for phenolics are the Fe(III)- and Ce(IV)-reducing capacity methods.

BACKGROUND: Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients. METHODS: Patients in whom mild-to-moderate dementia developed at least 2 years after they received a clinical diagnosis of Parkinson's disease were randomly assigned to receive placebo or 3 to 12 mg of rivastigmine per day for 24 weeks. Primary efficacy variables were the scores for the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change (ADCS-CGIC). Secondary clinical outcomes were the scores for the Alzheimer's Disease Cooperative Study-Activities of Daily Living, the 10-item Neuropsychiatric Inventory, the Mini-Mental State Examination, Cognitive Drug Research power of attention tests, the Verbal Fluency test, and the Ten Point Clock-Drawing test. RESULTS: A total of 541 patients were enrolled, and 410 completed the study. The outcomes were better among patients treated with rivastigmine than among those who received placebo; however, the differences between these two groups were moderate and similar to those reported in trials of rivastigmine for Alzheimer's disease. Rivastigmine-treated patients had a mean improvement of 2.1 points in the score for the 70-point ADAS-cog, from a baseline score of 23.8, as compared with a 0.7-point worsening in the placebo group, from a baseline score of 24.3 (P<0.001). Clinically meaningful improvements in the scores for the ADCS-CGIC were observed in 19.8 percent of patients in the rivastigmine group and 14.5 percent of those in the placebo group, and clinically meaningful worsening was observed in 13.0 percent and 23.1 percent, respectively (mean score at 24 weeks, 3.8 and 4.3, respectively; P=0.007). Significantly better outcomes were seen with rivastigmine with respect to all secondary efficacy variables. The most frequent adverse events were nausea (affecting 29.0 percent of patients in the rivastigmine group and 11.2 percent of those in the placebo group, P<0.001), vomiting (16.6 and 1.7 percent, P<0.001), and tremor (10.2 and 3.9 percent, P=0.01). CONCLUSIONS: In this placebo-controlled study, rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor.

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

IMPORTANCE: The prevalence of cardiometabolic multimorbidity is increasing. OBJECTIVE: To estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND PARTICIPANTS: Age- and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689,300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128,843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499,808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths). Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates. EXPOSURES: A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAIN OUTCOMES AND MEASURES: All-cause mortality and estimated reductions in life expectancy. RESULTS: In participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes and MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were little changed after further adjustment for markers of established intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a history of all 3 of these conditions was associated with 15 years of reduced life expectancy. CONCLUSIONS AND RELEVANCE: Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. Because any combination of these conditions was associated with multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity.